Filing Details

Accession Number:
0001689375-23-000011
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-03 16:32:04
Reporting Period:
2023-03-01
Accepted Time:
2023-03-03 16:32:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689375 Entrada Therapeutics Inc. TRDA Pharmaceutical Preparations (2834) 813983399
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741850 Nerissa Kreher C/O Entrada Therapeutics, Inc.
6 Tide Street
Boston MA 02210
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-01 28,400 $0.00 43,916 No 4 A Direct
Common Stock Disposition 2023-03-02 945 $11.60 42,971 No 4 F Direct
Common Stock Disposition 2023-03-02 1,477 $10.49 41,494 No 4 S Direct
Common Stock Disposition 2023-03-02 164 $11.22 41,330 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2023-03-01 43,000 $0.00 43,000 $12.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
43,000 2033-03-01 No 4 A Direct
Footnotes
  1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
  2. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
  3. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.04 to $11.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.04 to $11.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.